Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Hoffmann-La Roche
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06331598CT.gov A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) | — | Withdrawn | — | — | — |
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT06537310CT.gov A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06416436CT.gov Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | — | Withdrawn | — | — | — |
NCT05770102CT.gov DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | — | Recruiting | — | — | — |
NCT05944237CT.gov HTL0039732 in Participants With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT05907980CT.gov A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT04796012CT.gov VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT05525858CT.gov KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | Recruiting | — | — | — |
NCT05450562CT.gov Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
Show 32 more trialsShow fewer
NCT05159245CT.gov The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | — | Recruiting | — | — | — |
NCT04857138CT.gov A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04589845CT.gov Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | — | Active Not Recruiting | — | — | — |
NCT04642365CT.gov A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | — | Terminated | — | — | — |
NCT04185831CT.gov A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | — | Active Not Recruiting | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04101357CT.gov Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | — | Terminated | — | — | — |
NCT04303858CT.gov A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04250155CT.gov An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04196530CT.gov BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | — | Completed | — | — | — |
NCT04096638CT.gov Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03977467CT.gov Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | — | Completed | — | — | — |
NCT03835949CT.gov Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | — | Unknown | — | — | — |
NCT04276376CT.gov Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | — | Terminated | — | — | — |
NCT03673787CT.gov A Trial of Ipatasertib in Combination With Atezolizumab | — | Active Not Recruiting | — | — | — |
NCT03289962CT.gov A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | — | Completed | — | — | — |
NCT03264066CT.gov A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | — | Completed | — | — | — |
NCT02876510CT.gov ACTolog in Patients With Solid Cancers | — | Completed | — | — | — |
NCT02825940CT.gov A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02715531CT.gov A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | — | Completed | — | — | — |
NCT02650713CT.gov A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors | — | Completed | — | — | — |
NCT02541604CT.gov A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | — | Terminated | — | — | — |
NCT02543645CT.gov A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT02471846CT.gov A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02458638CT.gov A Study of Atezolizumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02350673CT.gov A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02410512CT.gov A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02304393CT.gov A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02091141CT.gov My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01988896CT.gov Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT01688206CT.gov A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT01375842CT.gov A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Hoffmann-La Roche | P2/3 | B · 62 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →